1-3 of 3
Aimee Foreman
Close
Sort by
Journal Articles

Cytogenetic and Molecular Responses after 2 Years of Tyrosine Kinase Inhibitor (TKI) Treatment in Simplicity, an Observational Study of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients (Pts) in Routine Clinical Practice

Jorge E. Cortes, MD, Stuart L. Goldberg, MD, Mauricette Michallet, MD PhD, Rüdiger Hehlmann, MD, Bengt Simonsson, MD, Michael J. Mauro, MD, Loretta A. Williams, PhD MSN, BSN, BA, Teresa Zyczynski, PharmD, MPH, MBA, BSPharm, Ginny P Sen, MPH, Aimee Foreman, MA, Srikanth Gajavelli, MD, Carlo Gambacorti-Passerini, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2894.
https://doi.org/10.1182/blood.V130.Suppl_1.2894.2894
Published: 2017
Journal Articles

Tyrosine Kinase Inhibitor (TKI) Switching Patterns during the First 12 Months in Simplicity, an Observational Study of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients (Pts) in Routine Clinical Practice

Stuart Goldberg, MD, Mauricette Michallet, MD PhD, Rudiger Hehlmann, MD, Teresa Zyczynski, PharmD, MPH, MBA, BSPharm, Aimee Foreman, Brian Calimlim, Ron Paquette, MD, Bengt Simonsson, MD, Carlo Gambacorti, MD PhD, Jorge E. Cortes, MD, Aleksandra Zagorska, Yuanxin Rong, Michael J. Mauro, MD
Journal: Blood
Blood (2016) 128 (22): 937.
https://doi.org/10.1182/blood.V128.22.937.937
Published: 2016
Journal Articles

Baseline Characteristics Of Patients With Chronic Myeloid Leukemia In a Prospective Observational Study (SIMPLICITY)

Jorge E. Cortes, MD, Rüdiger Hehlmann, MD, Carlo Gambacorti-Passerini, MD, Stuart Goldberg, MD, H. Jean Khoury, MD, Michael Mauro, MD, Mauricette Michallet, MD, PhD, Ron Paquette, MD, PhD, Bengt Simonsson, MD, PhD, Aimee Foreman, PhD, Hesham Mohamed, MD, Teresa Zyczynski, Pharm.D., MPH, Ishan Hirji, MPH, Catherine Davis, Pharm.D.
Journal: Blood
Blood (2013) 122 (21): 4026.
https://doi.org/10.1182/blood.V122.21.4026.4026
Published: 2013